Cellular Surgeons: The New Era of Nanomedicine - Full Program
Pills the size of molecules to seek and destroy tumors. Miniscule robots performing surgery inside patients with a precision never before achieved. Nanobots, a billionth of a meter across,...
By: World Science Festival
Excerpt from:
Cellular Surgeons: The New Era of Nanomedicine - Full Program - Video
DUBLIN--(BUSINESS WIRE)--The "Innovations in Wellness, Biotech, and Digital Health Platforms" report has been added to ResearchAndMarkets.com's offering.
This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) analyzes recent advances in 3D food printing for health & wellness, and latest developments across drug discovery, development, and delivery platforms. The TOE also provides insights across innovative precision therapy technologies and digital health platforms.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery, and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/acrspx
Go here to see the original:
Innovations in Wellness, Biotech, and Digital Health Platforms, 2019 Research Report - ResearchAndMarkets.com - Business Wire
With the outbreak of the Wuhan coronavirus in China and the increasing death toll, there is little doubt that global financial markets are going to be impacted negatively. As Trump considers banning all flights to China, airline and travel companies like United Airlines (NASDAQ:UAL), Expedia (NASDAQ:EXPE), American Airlines (NASDAQ:AAL) and many more have seen their stock prices crash. There is a strong negative sentiment on the Chinese economy as a whole as the virus has shaken up many of the erstwhile strong sectors.
Overview of the virus
For those readers who are not aware, the Wuhan coronavirus first emerged in the central Chinese city of the same name through the meat and seafood markets and has spread across the country with over a thousand cases and more than a hundred deaths confirmed. It belongs to the same family of viruses as SARS (severe acute respiratory syndrome) and the MERS (Middle East respiratory syndrome). This group of crown-shaped viruses can become deadly if it causes the patient to develop lower respiratory tract illnesses such as pneumonia or bronchitis. It is highly contagious in nature, spreading through the slightest form of saliva contact, whether it is coughing or kissing. The story of the Wuhan coronavirus sounds like history repeating itself after SARS shook up global markets in 2002-03.
It is worth recalling that pharma and biotech companies catering to the respiratory system and providing anti-viral medications were the ones that appreciated the most during the time of SARS, and the current situation does not appear very different. With a strong negative sentiment prevailing in most other sectors, pharma and biotech are perhaps the only sectors that could get a boost from a new bullish sentiment resulting from this virus. Based on the nature of the virus and the expected treatments, the following four stocks could benefit hugely given their presence in the field of anti-viral respiratory medication.
GlaxoSmithKline plc
Since the Wuhan coronavirus belongs to the same family as the SARS, it is important to recall those companies which benefitted the most from the SARS outbreak. While SARS may not have a defined cure even today, the most commonly prescribed form of treatment is the same as that for pneumonia. GlaxoSmithKline plc (NYSE:GSK) is one of the leaders in the space of anti-viral treatments for respiratory disorders like pneumonia.
The above chart shows how the company's stock grew as much as 35% during the SARS phase, which is quite significant for its size. It is worth highlighting that GlaxoSmithKline is a global player with its biggest markets being the U.S. and the UK. Respiratory oral health is one of its strongest segments, and it has a monopolistic position in many anti-viral medications. For example, its Shingrix vaccine for shingles is the only preventive vaccine for the disease across the globe. It has also performed strong research on HIV. The stock has appreciated by over 20% in the past twelve months and also provided a dividend yield of 4.32%, making it an excellent bet for investors.
Abbott Laboratories
Abbott Laboratories (NYSE:ABT) is more of a play on the diagnostics aspect rather than the treatment aspect of the Wuhan virus. The company is one of the largest global biotech giants, and one of its most important offerings relevant to the Wuhan virus situation is its diagnostic capabilities. Abbott is known to provide rapid diagnostics systems for infectious diseases along with remote patient monitoring, informatics and automation solutions that are all very relevant to diagnose the Wuhan virus victims. It also has molecular point-of-care testing for HIV, influenza A and B and RSV.
Story continues
Abbott's relevance was so strong in the SARS era that it appreciated by over 30% in those times and is already up by around 22% in the past 12 months. Given the current situation, the upward momentum of the stock might continue for a while.
Gilead Sciences, Inc.
Biotech giant Gilead Sciences, Inc. (NASDAQ:GILD) was easily one of the biggest beneficiaries in the SARS outbreak, as it saw its stock appreciate more than 200% throughout the outbreak.
The reason for this appreciation is that Gilead gets most of its revenues from the anti-viral segment. The company's stock price has been stable throughout economic downturns and it is not without reason that the company has a 4.5-star business predictability rating on Gurufocus. Not only is it debt-free, it is known to distribute a good amount of dividend (current yield of 3.93%) to shareholders over and above capital appreciation. Not only has it done remarkable research on HIV, Gilead also has some very well known anti-viral brands in the market such as Atripla, Cayston, Sovaldi, Odefsey, Truvada, Biktarvy and so on. It is certainly going to be moving fast in the race to provide strong anti-viral treatments for the Wuhan coronavirus.
NanoViricides, Inc.
NanoViricides, Inc. (NNVC) is the only small, development-stage company on this list, but it is here for a reason. Since the news of the Wuhan virus outbreak, NanoViricides has seen its stock shoot up by as much as 349%.
The company, led by biotech veteran Dr. Anil Diwan, specializes in anti-viral research and had actively worked on MERS in the past. Its current research is also focused on treating viruses through its proprietary nanomedicine technology, where it uses anti-viral nanomachines known as "nanoviricides." The company has a decent pipeline of anti-viral drug candidates catering to diseases such as shingles, herpes, seasonal and potentially-epidemic influenzas, bird flu, HIV, cold sores, viral eye diseases and dengue viruses.
In fact, its most rapidly advancing drug candidate is a topical cream for the treatment of shingles, which is now advancing to the stage of IND application before progressing to human trials. While the company may not have significant revenues today, it hopes to start monetizing the progress of this cream through licensing agreements after the initial phases of the human trials. It has been one of the biggest beneficiaries of the Wuhan virus outbreak so far in terms of stock appreciation, and the upward momentum is expected to remain strong with the IND application results arriving soon.
Conclusion
The Wuhan coronavirus may have a huge negative impact on global markets over a span of time, but the pharma and biotech space is one where it presents a good opportunity. As its fears grip the world, companies like the ones mentioned above are working hard to capitalize on this opportunity and maximize their revenues. In such a situation, it is often beneficial for investors to be opportunistic and make the most returns through investing in these companies.
Disclosure: No positions.
Read more here:
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
This article first appeared on GuruFocus.
Read this article:
These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus - Yahoo Finance
Nanomedicine: Ethical Issues and Societal Expectations
Speaker: PD Dr Johann S. Ach Academic Coordinator, Centre for Advanced Study in Bioethics, University of Mnster (D) CLINAM 7/ 2014, 7th Conference and Exhib...
By: TAUVOD
See the original post here:
Nanomedicine: Ethical Issues and Societal Expectations - Video
Nanomedicine Market 2019 report contains a focused socio-economic, political, and environmental analysis of the factors affecting the Nanomedicine industry. The report contains an analysis of the technologies involved in production, application and much more.
The report also carries in-depth case studies on the various countries which are actively involved in the Nanomedicine production. An analysis of the technical barriers, other issues, cost effectiveness affecting the Nanomedicine Market. Determining the opportunities, future of the Nanomedicine and its restraints becomes a lot easier with this report.
Request for Sample Copy of Nanomedicine Market Report athttps://www.pioneerreports.com/request-sample/46784
Details of Table of Content of Nanomedicine Market Report are as follows:
Chapter One Introduction of Nanomedicine Industry1.1 Brief Introduction of Nanomedicine1.2 Development of Nanomedicine Industry1.3 Status of Nanomedicine Industry
Chapter Two Manufacturing Technology of Nanomedicine2.1 Development of Nanomedicine Manufacturing Technology2.2 Analysis of Nanomedicine Manufacturing Technology2.3 Trends of Nanomedicine Manufacturing Technology
Chapter Three Analysis of Global Key Manufacturers3.1 Company A3.1.1 Company Profile3.1.2 Product Information3.1.3 2014-2019 Production Information3.1.4 Contact Information3.2 Company B3.2.1 Company Profile3.2.2 Product Information3.2.3 2014-2019 Production Information3.2.4 Contact Information3.3 Company C3.2.1 Company Profile3.3.2 Product Information3.3.3 2014-2019 Production Information3.3.4 Contact Information3.4 Company D3.4.1 Company Profile3.4.2 Product Information3.4.3 2014-2019 Production Information3.4.4 Contact Information&
Look into Table of Content of Nanomedicine Market Report at https://www.pioneerreports.com/TOC/46784
Regions Covered in Nanomedicine Market are:-
Chapter Four 2014-2019 Global and Southeast Asia Market of Nanomedicine4.1 2014-2019 Global Capacity, Production and Production Value of Nanomedicine Industry4.2 2014-2019 Global Cost and Profit of Nanomedicine Industry4.3 Market Comparison of Global and Southeast Asia Nanomedicine Industry4.4 2014-2019 Global and Southeast Asia Supply and Consumption of Nanomedicine4.5 2014-2019 Southeast Asia Import and Export of Nanomedicine
Chapter Five Market Status of Nanomedicine Industry5.1 Market Competition of Nanomedicine Industry by Company5.2 Market Competition of Nanomedicine Industry by Country (USA, EU, Japan, Southeast Asia etc.)5.3 Market Analysis of Nanomedicine Consumption by Application/Type
Chapter Six 2019-2024 Market Forecast of Global and Southeast Asia Nanomedicine Industry6.1 2019-2024 Global and Southeast Asia Capacity, Production, and Production Value of Nanomedicine6.2 2019-2024 Nanomedicine Industry Cost and Profit Estimation6.3 2019-2024 Global and Southeast Asia Market Share of Nanomedicine6.4 2019-2024 Global and Southeast Asia Supply and Consumption of Nanomedicine6.5 2019-2024 Southeast Asia Import and Export of Nanomedicine
Chapter Seven Analysis of Nanomedicine Industry Chain7.1 Industry Chain Structure7.2 Upstream Raw Materials7.3 Downstream Industry
Chapter Eight Global and Southeast Asia Economic Impact on Nanomedicine Industry8.1 Global and Southeast Asia Macroeconomic Environment Analysis8.1.1 Global Macroeconomic Analysis8.1.2 Southeast Asia Macroeconomic Analysis8.2 Global and Southeast Asia Macroeconomic Environment Development Trend8.2.1 Global Macroeconomic Outlook8.2.2 Southeast Asia Macroeconomic Outlook8.3 Effects to Nanomedicine Industry
Chapter Nine Market Dynamics of Nanomedicine Industry9.1 Nanomedicine Industry News9.2 Nanomedicine Industry Development Challenges9.3 Nanomedicine Industry Development Opportunities
Chapter Ten Proposals for New Project10.1 Market Entry Strategies10.2 Countermeasures of Economic Impact10.3 Marketing Channels10.4 Feasibility Studies of New Project Investment
Chapter Eleven Research Conclusions of Global and Southeast Asia Nanomedicine Industry
Key market insights include:
1. The analysis of Nanomedicine market provides market size and growth rate for the forecast period 2019-2024.
2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the Nanomedicine market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook of Nanomedicine market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.
In this study, the years considered to estimate the market size of Nanomedicine Market are as follows:-
Single User Licence Price: USD 3900
No Of Pages in Nanomedicine Market Report: 136
Purchase of Nanomedicine Market Report at:https://www.pioneerreports.com/checkout/46784
Continued here:
Nanomedicine Market Analysis Global Opportunities, Revenue, Demand and Geographical Forecast To 2024 - The Connection
Qualtrics increased its initial public offering range to $27 to $29 per share Monday, positioning the company to be the largest IPO to come from Utah.
Subscribe to the Crunchbase Daily
At that heightened price range, the company could be valued at up to $15 billion and raise about $1.5 billion through its IPO. Qualtrics, which provides software to help gauge employee, product, and customer experience and competes with companies like SurveyMonkey, previously set an IPO range of between $20 and $24 before raising it to between $22 and $26.
Qualtrics will be one of 67 public companies based in Utah, according to Crunchbase data. If it prices at the top of its range, it would raise nearly twice the amount of Utahs current largest IPO, EnergySolutions November 2007 initial public offering, which raised about $690 million.
Utahs burgeoning startup and tech scene isnt entirely new. The Provo-Lehi-Salt Lake City area is known as Silicon Slopes, and has created a tech community of its own. Venture-backed companies based in the state raised $1.2 billion in funding last year, per preliminary Crunchbase data.
But Qualtrics IPO is a big deal for the state, as was its previous exit when it was acquired by SAP. It could also lead to a flywheel effect for more big exits coming out of the state, according to Joe Kaiser, director of Utah-based Mercato Partners, a growth equity firm that invests in technology and consumer businesses.
Qualtrics has this cluster of incredibly talented people who were not here before it, but now are rooted in the Utah market, said Kaiser, a Utah transplant who moved to the state for business. He helped take Lehi, Utah-based Vivint Solar public in 2014 and ended up staying.
Now, when Qualtrics alums want to start the next cohort of great companies or the next generation of entrepreneurs is looking for leaders to help build their startups, theyll be able to tap a pool of talent created by companies like Qualtrics and Domo.
It has now incubated the local market with exceptional talent that now knows how to work in a hypergrowth environment that lacks structure initially, Kaiser said.
Qualtrics was on the verge of an IPO in November 2018 when enterprise software maker SAP announced plans to buy it for $8 billion. At the time, Qualtrics was SAPs second-largest acquisition ever, only behind the $8.3 billion acquisition of travel and expense management platform Concur, according to CNBC. The acquisition was also Utahs largest of the year.
SAP announced in July 2020 that it instead intended to take Qualtrics public after all, and the enterprise software-maker filed formally for an IPO for Qualtrics in December.
We decided that an IPO would provide the greatest opportunity for Qualtrics to grow the experience management category, serve its customers, explore its own acquisition strategy and continue building the best talent, SAP CEO Christian Klein said in a July statement. SAP will remain Qualtrics largest and most important go-to-market and research and development (R&D) partner while giving Qualtrics greater independence to broaden its base by partnering and building out the entire experience management ecosystem.
Qualtrics acquisition was one of two $1 billion-plus acquisitions to come from the state in 2019, with HealthEquity buying employee benefits manager WageWorks for $2.12 billion. It was also the largest acquisition of a Utah-based company ever, according to Crunchbase data. The $8 billion acquisition by SAP was around four times larger than the second-largest acquisition of a Utah company, when Blackstone bought Vivint Smart Home for $2 billion in September 2012.
As Kaiser put it, Utah companies are going for Silicon Valley prices, and he only expects transaction volume to climb. Mercato Partners portfolio companies have had five exits since March 2020, with three of those being over the $1 billion mark.
SoFi announced plans to acquire Salt Lake City-based Galileo Financial Technologies in April for $1.2 billion. Thoma Bravo acquired Venafi for $1.15 billion last year, and Ericsson bought Cradlepoint for $1.1 billion. Other notable recent acquisitions of Utah companies are VMWare buying SaltStack and Rubicon Technology Partners buying Central Logic.
Its not like one Utah company is buying another Utah company, this is much much broader than that, Kaiser said.
Qualtrics also marks the second notable public exit for a Utah-based company in recent months. Clene Nanomedicine, a biopharmaceutical company based in Salt Lake City, went public around three weeks after merging with a special purpose acquisition company.
To John Yoon, Mercato Partners vice president of marketing practice, tech companies being more flexible with remote work will only help Utahs burgeoning tech scene and the next generation of tech companies.
It starts with big companies encouraging people to move, or allowing people to move and once they move here, they dont have to stay with the big company. And thats where weve started to step in as investors, Yoon said, referring to the phenomenon as the pollination effect.
Startups in Utah will also benefit from the regional hubs that some large tech companies are starting to accommodate remote work, Kaiser said. Once talent moves to a place like Utah, Columbus or Minneapolis and settles down there, they could be more inclined to join a local startup.
Theyve set down roots, theyve seen how much easier life can be and they couple it with Now theres a cool startup in town and they need a backend engineer and this is what I do, Kaiser said.
Illustration: Li-Anne Dias
Editors Note: This story was updated Monday to reflect Qualtrics increased IPO price range.
Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.
Read this article:
Qualtrics IPO, Poised To Be Utah's Largest, Is Validation Of State's Burgeoning Tech Scene - Crunchbase News
CSIR-Centre for Cellular & Molecular Biology (CCMB) scientists in collaboration with CSIR-National Chemical Laboratory (NCL) announced on Thursday that they have made progress towards developing a non-toxic bio-drug derived from turmeric through a gene silencing approach to treat cancer.
RNA interference (RNAi) is a gene silencing approach and a promising tool for targeted and focused therapy for chronic diseases like cancer. The lack of safe and effective delivery methods for RNAi molecules is one of the key challenges against using RNAi-based therapy in biological systems.
CCMBs Dr. Lekha Dinesh Kumar and her group in collaboration with NCLs polymer science and engineering division have developed nano-curcumin structures (derived from turmeric) to encapsulate the RNAi and other molecules that aid in targeting specific tissues.
The proposed bio-drug is bio-compatible with a higher uptake efficiency, and shows effective site-specific delivery with regression of tumors in two different mouse models of colon and breast cancer. The use of curcumin, a well-known nutraceutical with high anti-cancer and anti-inflammatory properties with RNAi, showed tumor retardation with six months survival in aggressive models of colon and breast cancer, says Dr. Kumar.
Cancer is one of the leading causes of death worldwide and the quest to find plausible therapeutic interventions to replace non-specific chemo drugs has been leading to the development of novel strategies to combat cancer. This work has been published in the journal Nanoscale.
In another study with the School of Nanosciences, Central University, Gujarat and Centre for Advanced Materials and Industrial Chemistry, RMIT Australia, they designed an eco-friendly and pH-responsive dietary fibre inulin-based nanodevice to target colon cancer.
This device suggests the possibility of substituting synthetic substances with natural compounds in bio-drug formulations for better bio-degradability, tissue accumulation, and lesser toxicity.
The results from this work have been published in the journal Nanomedicine, said an official release.
We have demonstrated that RNAi combined with appropriate targeting agents and encapsulations made of natural biomaterials have high translational capacity in mice models of cancer. This group of bio-drugs can revolutionize cancer therapeutics. But, it should be assessed in other cancer model systems to bring out the utility of these therapeutics in the clinical trials, she added.
Read this article:
Now, a bio-drug derived from turmeric to treat cancer - The Hindu
Oct. 13, 2020 06:00 UTC
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the first patient has been injected in its phase I study evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer. The trial is a being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.
Two additional trials from the clinical collaboration received safe to proceed notifications from the United States Food and Drug Administration (FDA): (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation; and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. All current and future trials in this clinical collaboration are sponsored and executed by MD Anderson.
A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with Pancreatic Cancer
Pancreatic cancer is a rare, deadly disease that accounts for approximately 3% of all cancers and has a 5-year survival rate of 9%1.
This pancreatic cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D) of NBTXR3 activated by radiation therapy; and (ii) expansion at RP2D.
The patient population will include adults (age 18 years) with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. Up to 24 subjects will be enrolled and the planned enrollment period is 18 months.
The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.
Two Additional Phase I Studies in Lung and Esophageal Cancer Pending
A phase I trial investigating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation, and a phase I trial investigating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer have been deemed safe to proceed by FDA. Safe to proceed notifications are delivered once the agency is satisfied with the information contained in an investigational new drug application (IND) or any additional information or clarification has been provided.
Lung cancer is the second most common cancer type, and the leading cause of cancer death for both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5-year survival rate of 24% worldwide.2
The lung cancer trial is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D; and (ii) expansion at the RP2D with toxicity monitoring.
The patient population will include adults (age 18 years) with inoperable, locoregional recurrent (LRR) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (IMRT) monotherapy in 10 patients. Up to 24 subjects will be enrolled in cohort 2. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 36 months.
Esophageal cancer is the eighth most common cancer type and the sixth most common cause of cancer deaths worldwide. The 5-year survival rate in the US is 20%, and 10% in Europe3.
The esophageal cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiation therapy with concurrent chemotherapy, as per standard of care; and (ii) expansion at the RP2D with toxicity monitoring.
The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment nave and radiographically non-metastatic at screening. Up to 24 subjects will be enrolled. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 24 months.
Next Steps for Clinical Collaboration with MD Anderson
The clinical collaboration between Nanobiotix and MD Anderson includes plans for additional clinical trials across several indications. Beyond the three (3) trials mentioned above, the other trials, including four (4) combination trials with immune checkpoint inhibitors and NBTXR3 activated by radiation therapy, are in preparation and will launch in due time.
***
About NBTXR3
NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.
NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.
Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.
Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
1 https://www.cancer.net/cancer-types/pancreatic-cancer/statistics
2 https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics
3 https://www.cancer.net/cancer-types/esophageal-cancer/statistics
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005825/en/
Read the original:
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From US FDA -...
A UB-led research team has discovered a technique that could help increase the effectiveness of vaccines against the novel coronavirus, the virus that causes COVID-19.
Jonathan F. Lovell, associate professor in the Department of Biomedical Engineering, is the primary investigator on the research, titled SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination, which was published online today in Advanced Materials.
COVID-19 has caused a disruptive global pandemic, infecting at least 40 million worldwide and causing more than 220,000 deaths in the United States alone. Since it began spreading in early 2020, biomedical researchers have been in active pursuit of an effective vaccine.
According to Lovell, one answer might lie in designing vaccines that partially mimic the structure of the virus. One of the proteins on the virus located on the characteristic COVID spike has a component called the receptor-binding domain, or RBD, which is its Achilles heel. That is,he says, antibodies against this part of the virus have the potential to neutralize the virus.
It would be appealing if a vaccine could induce high levels of antibodies against the RBD, Lovell says. One way to achieve this goal is to use the RBD protein itself as an antigen; that is, the component of the vaccine that the immune response will be directed against.
The team hypothesized that by converting the RBD into a nanoparticle (similar in size to the virus itself) instead of letting it remain in its natural form as a small protein, it would generate higher levels of neutralizing antibodies and its ability to generate an immune response would increase.
Lovells team had previously developed a technology that makes it easy to convert small, purified proteins into particles through the use of liposomes, or small nanoparticles formed from naturally occurring fatty components. In the new study, the researchers included within the liposomes a special lipid called cobalt-porphyrin-phospholipid, or CoPoP. That special lipid enables the RBD protein to rapidly bind to the liposomes,forming more nanoparticles that generate an immune response, Lovell explains.The team observed that when the RBD was converted into nanoparticles, it maintained its correct, three-dimensional shape and the particles were stable in incubation conditions similar to those in the human body. When laboratory mice and rabbits were immunized with the RBD particles, high antibody levels were induced. Compared to other materials that are combined with the RBD to enhance the immune response, only the approach with particles containing CoPoP gave strong responses.
Other vaccine adjuvant technology does not have the capacity to convert the RBD into particle-form, Lovell notes.
We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being inparticle format, he says. This could help inform future vaccine design that targets this specific antigen.
Lovells co-authors on the study include Wei-Chiao Huang, Shiqi Zhou, Xuedan He and Moustafa T. Mabrouk, all from the UB Department of Biomedical Engineering; Kevin Chiem and Luis Martinez-Sobrido, both from Texas Biomedical Research Institute; Ruth H. Nissly, Ian M. Bird and Suresh V. Kuchipudi, all from the Animal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences at Pennsylvania State University; Mike Strauss and Joaquin Ortega from the Department of Anatomy and Cell Biology at McGill University; Suryaprakash Sambhara from the Immunology and Pathogenesis Branch of the U.S. Centers for Disease Control and Prevention; Elizabeth A. Wohlfert from the UB Department of Microbiology and Immunology; and Bruce A. Davidson from the Department of Anesthesiology and the Department of Pathology and Anatomical Sciences at UB.
Lovell founded the Lovell Lab at UB in 2012. It is focused on developing novel nanomedicine approaches to meet unmet needs in treating and preventing disease. He is also a co-founder of POP Biotechnologies Inc., a preclinical stage biotechnology company developing next-generation drug and vaccines products.
The study was supported by the U.S. National Institutes of Health and the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, Quebec Government and McGill.
Read the original:
Transforming coronavirus protein into a nanoparticle could be key to effective COVID-19 vaccine - UB Now: News and views for UB faculty and staff -...
The global Nanomedicine Market Reports review the latest Nanomedicine market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for particular sector investments. the study reveals profitable investment strategies for Nanomedicine companies, business executives, product marketing managersand new business investors..
report evaluates the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. global Nanomedicine Market Growth has also been forecasted for the period 2020-2025, compelling into consideration the previous growth patterns, the growth drivers and the current and future trends.
Get a Sample Copy of the Report at-https://www.absolutereports.com/enquiry/request-sample/15462802
The global Nanomedicine market consists of a number of players. The company outlining of the below market players has been done in the report consisting of their business overview, financial overview and the business strategies adopted by the companies.
Nanomedicine Market Report Highlights key Market Dynamics of sector, Various definitions and classification of applications of the Nanomedicine market industry and Chain structure with Upstream Raw Materials, Sourcing Strategy and Downstream Buyers are given. Additionally, prime strategical activities in the market, which includes Nanomedicine market share, product developments, mergers and acquisitions, partnerships, etc., are discussed.
Key Companies
Market Segmentation of Nanomedicine market
Market by Application
Market by Type
Inquire Or Share Your Questions If Any Before The Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/15462802
By Region
Key Topic Covered in Nanomedicine Market Report
Answered to the Frequently Asked Questions
WHAT IS THE SCOPE OF THE REPORT?
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
WHAT ARE THE KEY SEGMENTS IN THE MARKET?
WHICH MARKET DYNAMICS AFFECTS THE BUSINESS?
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Purchase This Report (Price 4500 USD for single user license) https://www.absolutereports.com/purchase/15462802
Detailed Table of Content of Global Nanomedicine Market 2020-2025
Table of ContentsPart 1 Market Overview1.1 Market Definition1.2 Market Development1.3 By TypeTable Type of NanomedicineFigure Global Nanomedicine Market Share by Type in 20201.4 By ApplicationTable Application of NanomedicineFigure Global Nanomedicine Market Share by Application in 20201.5 Region OverviewTable Region of NanomedicineFigure Global Nanomedicine Market Share by Region in 2020Part 2 Global Market Status and Future Forecast2.1 Global Market by RegionTable Global Nanomedicine Market by Region, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Region in 2020 (Million USD)Table Price List by Region, 2015-20192.2 Global Market by CompanyTable Global Nanomedicine Market by Company, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Company in 2020 (Million USD)Table Price List by Company, 2015-20192.3 Global Market by TypeTable Global Nanomedicine Market by Type, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Type in 2020 (Million USD)Table Price List by Type, 2015-20192.4 Global Market by ApplicationTable Global Nanomedicine Market by Application, 2015-2019 (Million USD)Figure Global Nanomedicine Market Share by Application in 2020 (Million USD)Table Price List by Application, 2015-20192.5 Global Market by ForecastFigure Global Nanomedicine Market Forecast, 2020-2024 (Million USD)Part 3 Asia-Pacific Market Status and Future Forecast3.1 Asia-Pacific Market by CompanyTable Asia-Pacific Nanomedicine Market by Company, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Company in 2020 (Million USD)Table Price List by Company, 2015-20193.2 Asia-Pacific Market by TypeTable Asia-Pacific Nanomedicine Market by Type, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Type in 2020 (Million USD)Table Price List by Type, 2015-20193.3 Asia-Pacific Market by ApplicationTable Asia-Pacific Nanomedicine Market by Application, 2015-2019 (Million USD)Figure Asia-Pacific Nanomedicine Market Share by Application in 2020 (Million USD)Table Price List by Application, 2015-2019
.And Many more.
For Detail TOC Click Here
Contact Info:
Name: Ajay More
Email: [emailprotected]
Organization: Absolute Reports
Phone: +14242530807/+44203239 8187
Our Other report :Motion Tracker Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026
Global Underwater Exploration Robots Market 2024: Size, Key Companies, Trends, Growth and Regional Forecasts Research
Osteotomy Plates Market 2020 Capacity Production Overview, Market Share Analysis, Demand Overview, Import Export Consumption
COVID-19 Outbreak- Global Bacterial Diagnostics in Aquaculture Market 2020 Key Players, Industry Overview, Supply Chain and Analysis to 2025
Global Permanent Magnetic Material Market Growth Factors, Product Types and Application by Regions Analysis & Forecast by 2026
Worldwide Phthalate Plasticizers Market Outlook to 2025: Emerging Trends and Will Generate New Growth Opportunities Status
Global Benazepril Market 2021: Overview, Manufacturing Cost Structure Analysis, Growth Opportunities Forecaste 2025
Global Tire Release Agents Market Outlook 2025: Top Companies, Trends and Future Prospects Details for Business Development
Global Cosmetic Nonsurgical Surgery and Procedure Market 2021: Boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2025
Global Radiation Cure Coatings Sales Market 2021: Market Growth, Trends, Revenue, Share and Demands Research Report|Coronavirus Impact
Global Recombinant Protein Vaccine Market 2020: Market Size, Share, Growth, Sales and Drivers Analysis Research Report 2024 with
Global Field-Mount Temperature Transmitters Sales Market 2026: Size, Key Companies, Trends, Growth and Regional Forecasts Research|Coronavirus Impact
Global High Performance Biomaterials Sales Market 2021: Industry Size, Outlook, Share, Demand, Manufacturers and 2026 Forecast Researchs|Coronavirus Impact
Follow this link:
Nanomedicine Market Analysis and Forecast to 2025 by Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview Murphy's...
IMAGE:Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injectedview more
Credit: Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas. The radiotracer proved to be a superior, high-contrast imaging diagnostic in patients, visualizing tumors that express low or moderate levels of v3 integrin with high sensitivity.
Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults, with 17,000 diagnoses annually. It is a highly diffuse and invasive disease that is personally devastating and virtually incurable. Once diagnosed, most patients survive less than 15 months, and fewer than five percent survive five years.
The 64Cu-EBRGD radiotracer presented in this study has several unique qualities. The peptide sequence Arg-Gly-Asp (RGD) specifically targets the cell surface receptor v3 integrin, which is overexpressed in glioblastomas. To slow clearance, Evans Blue (EB) dye, which reversibly binds to circulating albumin, is bound to RGD, significantly enhancing target accumulation and retention. The addition of the 64Cu label to EBRGD provides persistent, high-contrast diagnostic images in glioblastoma patients.
This first-in-human, first-in-class study included three healthy volunteers who underwent whole-body 64Cu-EBRGD PET/CT. Safety dataincluding vital signs, physical examination, electrocardiography, laboratory parameters and adverse eventswere collected after one day and after one week. Regions of interest were drawn, time-activity curves were obtained and dosimetry was calculated. Two patients with recurrent glioblastoma also underwent 64Cu-EBRGD PET/CT. Seven sets of brain PET and PET/CT scans were obtained over two consecutive days. Tumor-to-background ratios were calculated for the target tumor lesion and normal brain tissue. One week after radiotracer administration, the patient underwent surgical treatment, and immunohistochemical staining of tumor samples was performed.
64Cu-EBRGD was well-tolerated in patients with no adverse symptoms immediately or up to one week after administration. The mean effective dose of 64Cu-EBRGD was very similar to the effective dose of an 18F-FDG scan. Injection of 64Cu-EBRGD to the patients with recurrent glioblastoma showed high accumulation at the tumor with continuously increased tumor-to-background contrast over time. Post-operative pathology revealed World Health Organization grade IV glioblastoma, and immunohistochemical staining showed moderate expression of the v3 integrin.
In this study, we have demonstrated a potential radiotheranostic agent that is safe, sensitive and highly selective in humans, which infers a future diagnostic tool and breakthrough targeted radiotherapy for glioblastoma patients, said Jingjing Zhang, MD, PhD, of Peking Union Medical College Hospital, Beijing, China. We believe this innovative use of 64Cu-EBRGD will significantly improve therapeutic efficacy and patient outcomes.
64Cu-labeled EBRGD represents a viable model compound for therapeutic applications since 177Lu, 90Y or 225Ac can be substituted for 64Cu, said Deling Li, MD, of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. We are currently studying the 177Lu homolog to treat glioblastoma and other v3 integrin expressing cancers, including non-small cell lung, melanoma, renal and bone, and hope to build on the current wave of radiotherapies like 177Lu-DOTATATE.
###
Abstract 349. First-in-Human Study of a 64Cu-Labeled Long-acting Integrin v3 Targeting Molecule 64Cu-NOTA-EB-RGD in Healthy Volunteers and GBM Patients, Jingjing Zhang, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, and THERANOSTICS Center for Radiomolecular Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; Deling Li, Department of Neurosurgery Beijing, Tiantan Hospital, Beijing City, China; Gang Nu, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland; Richard Baum, THERANOSTICS Center for Radiomolecular Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; Zhaohui Zhu, Department of Nuclear Medicine, Peking Union Medic, Beijing, China; and Xiaoyuan Chen, NIBIB/NIH, Bethesda, Maryland. SNMMIs 67th Annual Meeting, July 11-14, 2020.
Molecular Targeting Technologies, Inc., received an exclusive worldwide commercialization license from NIH for rights that, in part, cover EBRGD radiotherapeutics using various radionuclides. Glioblastoma treatment is among its potential uses.
All 2020 SNMMI Annual Meeting abstracts can be found online at http://jnm.snmjournals.org/content/61/supplement_1.toc.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMIs members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.
Read the original here:
Report: New PET radiotracer proven safe and effective in imaging malignant brain tumors - Tdnews
The potential of Nanomedicine: why is small different?
Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.
Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.
At the nano-scale, the surface-to-volume ratio is such that the surface properties are becoming an intrinsic parameter of the potential actions of a particle or material. Coating of the particles and functionalization of their surfaces (even on multiple levels) are in this way extremely common to increase the biocompatibility of the particle and its circulation time in the blood, as well as to ensure a highly selective binding to the desired target.
Nanomedicine has the potential to enable early detection and prevention and to drastically improve diagnosis, treatment and follow-up of many diseases including cancer but not only. Overall, Nanomedicine has nowadays hundreds of products under clinical trials, covering all major diseases including cardiovascular, neurodegenerative, musculoskeletal and inflammatory. Enabling technologies in all healthcare areas, Nanomedicine is already accounting for approximatively 80 marketed products, ranging from nano-delivery and pharmaceutical to medical imaging, diagnostics and biomaterials.
Visit link:
What is nanomedicine? | ETPN
Inigo Charola, CEO EthicaMeat
Ethicameat is the cultivated meat brand of Biotech Foods, a pioneering Spanish company that says it is driving a revolution in the global food market; natural slaughter-free animal meat. Ethicameat says it is addressing the high demand for animal-based protein and reducing the current impact of the production process on the environment through sustainable solutions.
We were pleased to speak with Iigo Charola, CEO of Biotech Foods about their brand EthicaMeat, the future of protein and the role in which cultured meat will play.
Who is the team behind Ethica Meat?The company comprises a diverse team of experts in biomedicine, specialising in tissue regeneration and nanomedicine, which covers process engineering and pharmacology and biotechnology, in combination with a deep understanding of the food market.
Mercedes Vila is our Co-Founder and CTO of Ethicameat. She has a PhD in Materials Physics from the Autonoma University of Madrid-CSIC, and more than 16 years of experience in the design and application of materials in biomedicine and the understanding of surface interactions between cells and materials. In 2010 she was awarded the LORAL-UNESCO For Women in Science Prize in recognition of her scientific career. In 2012 she was appointed Distinguished Researcher through the I3 Programme of the Spanish Ministry of Science and Technology and she has been awarded three times the Marie-Sklodowska Curie Action of the European Commission.
Since the beginning of her career Vila has worked on the possibilities offered by tissue engineering and nanomedicine in the field of regeneration and treatment of the human body. In 2017 Vila cofounded BioTech Foods, the company that produces Ethicameat, the cultivated meat brand of Biotech Foods.
Iigo Charola is CEO and Co-Founder of BioTech Foods. He has a degree in Business Administration from the University of Wales, a Masters in Marketing Management from the prestigious ESIC Business & Marketing School and an MBA from the University of Deusto, as well as numerous leadership programs in Business Administration. He has developed his career as business director in several industries, including food technology, for more than 20 years.
Why cultured meat, and why now?Factory farming meat production model is developed on an unsustainable scale for a depleted planet. Today, factory farming accounts for 25% of the land and water use on the planet and 15% of greenhouse gas emissions. Sustained development of this model is threatening the existing and long-term capacity of the Earths resources. We are therefore facing the challenge of an unsustainable model in the long-term.
Global demand for protein currently stands at 202 million tonnes a year. This includes all types of meat and fish. This demand is forecast to increase to 1000 million tonnes by 2050, according to the latest data from the Food and Agriculture Organization (FAO) of the United Nations. This means that it is essential to find a sustainable alternative that, combining the most advanced technology with environmental protection, meets future demand.
Cultivated meat production uses much fewer resources: 99% less land, 75% less water and 90% fewer greenhouse gas emissions than similar meat products.
What is your company mission and how do you hope to achieve it?The mission of BioTech Foods is to commit to the construction of a world in which anyone who wants to eat meat can do so without killing an animal. A world where animal welfare, food safety and innovation would be the values that drive our species out to a more sustainable planet.
What will your portfolio be and when will the products be available?BioTech Foods works on pork meat and have plans to expand to poultry after that. We are currently developing our product offering for the consumer. Biotech Foods is collaborating with meat processing companies to obtain the final format of Ethicameat products, that will be launched in a range of consumer products such as sausages, ham and nuggets. The selected species give us a huge variety of potential products. Ethicameat is currently in the production scaling and regulation stage, before starting with the commercialization.
Where will your products be on sale, in which markets?Biotech Foods is collaborating with meat processing companies to obtain the final format of Ethicameat products that will be launched initially in the EU and in the US after first market introduction.
Are you seeking partners? We are very proud of the fact that our company already has raised over 2.5 million euros and our plan is to reach our short-term goals. We think collaboration is key to bring this new products into the market, so we keep collaborations in all parts of the value chain and we expect to keep growing those collaborations.
What are your plans for 2020 and the next few years?We now have the technology developed and we are now in the scale up process to bring cultivated meat to industrial production.
In the long term, we want to become a consumer alternative to traditional meat, a means to a much more important goal: sustainability between meat consumption, respect for animal welfare and the environment.
How do you foresee the future of the meat industry and which part will cultivated meat play? Are people ready for it in 2020? There are different forecasts about how protein consumption is going to evolve. What all of them have in common is that they predict a decrease of consumption of factory farming meat and plant bases and cultivated meat to be a substantial part of the proteins we consume. Some reports estimate this trend will keep rising to 2040, when cultivated meat will have a 35% share of all protein consumption.
Both production methods will undoubtedly co-exist because the consumer will demand it, but there seems to be no doubt that the overall production model will benefit.
Related
Here is the original post:
EthicaMeat: Committed to Constructing a "World in Which Anyone Who Wants to Eat Meat Can do so Without Killing an Animal" - vegconomist -...
The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Nanomedicine Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.
It offers detailed research and analysis of key aspects of the global Nanomedicine market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Nanomedicine market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Nanomedicine market is carefully analyzed and investigated by market analysts.
For Better Understanding, Download Sample PDF Copy of Nanomedicine Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=LHN&utm_medium=888
**Our SAMPLE COPY of the report gives a brief introduction of the Nanomedicine market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**
The Major Players in Global Nanomedicine Market:
Global Nanomedicine Market Segmentation
This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.
To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=LHN&utm_medium=888
Nanomedicine Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Some Notable Report Offerings:
-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.
-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Nanomedicine industry.
-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Nanomedicine industry.
-> Furthermore, we will help you to identify any crucial trends to predict Nanomedicine market growth rate up to 2026.
-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Nanomedicine market.
Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=LHN&utm_medium=888
Table of Contents:
Study Coverage: It includes study objectives, years considered for the research study, growth rate and Nanomedicine market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.
Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Nanomedicine market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.
Nanomedicine Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.
Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.
About Us:
Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.
Contact Us:
Mr. Steven Fernandes
Market Research Intellect
New Jersey ( USA )
Tel: +1-650-781-4080
Tags: Nanomedicine Market Size, Nanomedicine Market Growth, Nanomedicine Market Forecast, Nanomedicine Market Analysis
Our Trending Reports
Commercial Greenhouse Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026
Deep Learning Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026
Digital Out Of Home Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026
See original here:
Nanomedicine Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald
Short Name: Nanomed Meeting 2017
Theme: Challenges and Innovations in next generation medicine
Website: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology
Registration Link: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology/registration
Nanomed Meeting 2017 Organizing Committee invites you to attend the largest assemblage of Nanomedicine and Nanotechnology researchers from around the globe during November 23-24, 2017 at Dubai, UAE.
Nanomed Meeting 2017 is a global annual event. This International Conference and Exhibition on Nanomedicine and Nanotechnology brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Nanomed Meeting 2017 through a decade at Asia finds much requirement for discussion also focusing the latest developments in the field of Nanomedicine and Nanotechnology.
Why attend?
Join your peers around the world focused on learning about Nanomedicine and Nanotechnology related advances, which is your single best opportunity to reach the largest assemblage of participants from the Nanomedicine and Nanotechnology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Nanomedicine and Nanotechnology are hallmarks of this conference.
Like what you just read? You can find similar content on the communities below.
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
Read more:
International Conference and Exhibition on Nanomedicine and Nanotechnology - Technology Networks
Researchers at the University of Calgary say their work in the field of "nanomedicine"could lead to cures for Type 1 diabetes, multiple sclerosis and many more diseases.
Dr. Pere Santamaria said the process involves "nanoparticles" thousands of times smaller than a typicalhuman cell that could be used to stop the body from attacking itself.
That, he said, could potentially lead to cures for autoimmunedisorders.
"There are no drugs that can do that today,"said Santamaria, aprofessor ofimmunology at the University of Calgary.
"Other drugs that are being used to treat chronic inflammatory disorders impair the ability of the immune system to do its job, so there are secondary effects and longterm complications our drugs don't do that."
Pharmaceutical company Novartis has partnered with Santamaria's own company, Parvus Therapeutics, to work on developing the nanomedicines and take the drugs to market.
Now with support and funding, Santamariasaid the new drug"has the potential to revolutionizemedicine" if the drugs pass clinical testing.
Santamariasaid autoimmune disordersarecaused by white blood cells attacking the tissues in a person'sown body.
Pharmaceutical company Novartis has partnered with Dr. Santamaria's Parvus Therapeutics to work on developing nanomedicines to cure autoimmune disorders and take the drugs to market. (CBC)
Type 1 diabetesis treatable with insulin, but there is no cure. It's the same for many other diseases.
"Our drugs aim to resolve the inflammation of the tissue, the attack of the tissue, and resolve that process altogether," Santamaria said.
He said the nanoparticles could halt disorders without impairing the rest of the immune system.
"So we can reset the immune system to its steady state that means the healthy state without impairing the ability of our immune system to protect us against infections and cancer,"Santamariasaid.
Santamaria said the nanoparticleswere discovered during an experiment years ago, and the initialtestresults"made nosensewhatsoever." Since that day, the nanomedicines havebeen in development and he credits the progress to curiosity.
"We almost shoved them under the rug," Santamaria said."We didn't do that. Fortunately, we were pursued wth curiosity of researching."
Santamaria said the process of taking a discovery from the research laboratory to the marketplace is enormously complex and the drug has yet to go through preclinical trials.
Because nanomedicine is such a new field of research, there is no firm timeline on when the medicinescould be available if they pass human trials.
"Our nanomedicineis a new class of drug ... so we're basically blazing the trail," Santamaria said.
"We hope that we can carry that torch and be an example for all the investigators that might follow suit, that may run into discoveries such as the ones that we've made and hopefully they can follow in our footsteps."
View original post here:
'Blazing the trail': University of Calgary research could lead to cures for autoimmune diseases - CBC.ca
JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page.Abstract
Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to demonstration of therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. We should evolve our nanomedicine development strategies to build the patient and disease into the line of sight from the outset. The success of small molecule targeted therapies has been significantly improved by employing a specific decision-making framework, such as AstraZeneca's 5R principle: right target/efficacy, right tissue/exposure, right safety, right patient, and right commercial potential. With appropriate investment and collaboration to generate a platform of evidence supporting the end clinical application, a similar framework can be established for enhancing nanomedicine translation and performance. Building informative data packages to answer these questions requires the following: (I) an improved understanding of the heterogeneity of clinical cancers and of the biological factors influencing the behaviour of nanomedicines in patient tumours; (II) a transition from formulation-driven research to disease-driven development; (III) the implementation of more relevant animal models and testing protocols; and (IV) the pre-selection of the patients most likely to respond to nanomedicine therapies. These challenges must be overcome to improve (the cost-effectiveness of) nanomedicine development and translation, and they are key to establishing superior therapies for patients.
Nanomedicine
EPR effect
Clinical translation
Pre-clinical models
Industry
Companion diagnostics
Patient pre-selection
Recommended articlesCiting articles (0)
2016 The Author(s). Published by Elsevier B.V.
Go here to see the original:
Challenges and strategies in anti-cancer nanomedicine ...
Targeted Nanomedicine Treats Advanced-stage Ovarian Cancer
Rutgers University scientists have utilized a targeted nanomedicine approach to deliver small molecule medicationss and successfully treat mice with deadly a...
By: EmpoweredDoctor
See more here:
Targeted Nanomedicine Treats Advanced-stage Ovarian Cancer - Video
Ethical, Legal, Social and Economic Aspects of Nanomedicine
Lecture of Dr. Klaus-Michael Weltring, Chair of WG Eyhics in ETPN. The lecture was performed at the Training Workshop on Ethical Issues in Nanomedicine, the ...
By: Michael Beigel
See the original post here:
Ethical, Legal, Social and Economic Aspects of Nanomedicine - Video
Share
Share
Nanomedicine and drug delivery systems are at the forefront of modern healthcare. These systems offer a new platform for drug delivery that can greatly increase the targeting and effectiveness of therapy.
Over the last twenty years, great strides have been made in cancer nanomedicine and tissue repair using targeted drug delivery systems. In this field, the goal is to take advantage of the unique properties of a material on the nanoscale to minimize toxicity in healthy organs by specifically targeting cancerous cells. Our research group has sought to develop safer and more efficacious therapies in order to advance patient care and clinical outcomes.
Concerning nanomedicine, the focus of our research has been to improve the treatment of different types of cancer, among them lymphoma and glioma. We have developed polymeric and lipid nanoparticles loaded with different antitumor agents, such as edelfosine, which presents the singular characteristic of not targeting the cells DNA but the cell membrane and the apoptotic machinery of the cancer cell. These nanosystems were able to cross the blood-brain barrier, and furthermore, in the case of lymphoma models, they were found to successfully inhibit not only the primary tumor, but also its spread to other parts of the body when administered orally.
More recently, our attention has been centered on the use of nanotechnology for the treatment of pediatric cancers, particularly osteosarcoma, which is the most frequently observed primary malignant bone tumor in the pediatric population. We have shown that our nanomedicines decreased the toxicity of the entrapped edelfosine, and that this treatment slowed the progression of the primary tumor growth in orthotopic osteosarocoma animal models, successfully preventing the metastatic spread of the osteosarcoma cells from the primary tumor to the lungs these findings were significant as it is assumed that 80% of patients with osteosarcoma present non-detectable micrometastases at diagnosis. The nanomedicines we have developed, and more specifically lipid based nanosystems entrapping edelfosine, could provide a more effective and safer alternative to conventional treatments for different types of cancers.
Regenerative medicine has also been of great interest to us. It is an interdisciplinary field that promotes regeneration of tissue or organs damaged by disease, which contrasts with traditional strategies that focus primarily on treating symptoms. In this sense, our focus has been the development of novel drug delivery systems to provide better treatment for brain and cardiac diseases. A large number of the projects carried out by our group have been done in collaboration with clinicians, pharmaceutical scientists, material engineers, and veterinarians, leading to novel delivery systems in key areas of unmet medical needs such as Parkinsons disease and myocardial infarction.
Specifically, our biomaterials can solve one of the greatest issues associated with biotherapeutic formulation and delivery, which is their fast degradation. In order to overcome this challenge, we have designed various microparticle-based technologies which we are able to protect biomolecules from degradation in biological environments. Our technique avoids shear stress and preserves the proteins from degradation during the manufacture process.
We have demonstrated that the injection of microparticles loaded with glial cell line-derived neurotrophic factor (GDNF) one of the most promising candidates for the treatment of Parkinsons disease within the brain of animals with severe nigrostriatal degeneration achieved long-term improvement in motor function, which was associated with the restoration of the dopaminergic function.
Similar to the positive results observed in the treatment of Parkinsons disease, we also observed improved cardiac recovery after myocardial infarction after treatment with neuregulin or fibroblast growth factor loaded microparticles. Interestingly, these microparticles modulated the inflammatory process towards a reparative response. However, we are only starting to obtain a glimpse into the crucial role of the inflammatory response for tissue repair. More studies addressing the contribution of different macrophage subsets to the reparative process are mandatory to fully understand the therapeutic potential of modulating the inflammatory response, as therapeutic treatment not only for myocardial infarction, but also for several other diseases, including cancer.
Beyond assessing the efficacy of microencapsulated biotherapeutics, microparticle optimization has also been a regular topic of discussion in the research group. The hydrophilic polymer coating, poly (ethylene glycol) (PEG), is well-known to increase the half-life of biotherapeutics and to reduce particle clearance in the blood, but the same strategy has not proven effective in reducing particle elimination in the heart. PEG decreases particle clearance in the blood by blocking opsonins, macromolecules that bind particles and mark them to be eliminated by phagocytes. However, in the cardiac tissue, particle clearance may not be dependent on opsonins which would explain why PEG failed to improve microparticle bioavailability in the heart.
Mirco- and nanoparticle-based drug delivery systems combined with cell therapy can achieve a more complete and potent regenerative response. Indeed, biomimetic biomaterials with tunable properties can be tailored to influence the fate of transplanted cells and to improve current cell delivery strategies. Within this framework, the use of microparticles as delivery vehicles for stem cells and human cardiomyocytes has proven to maximize the efficacy of cell therapy by dramatically enhancing cell survival in the heart. Cutting-edge areas such as non-invasive intravenous delivery of cardioprotective nanomedicines or extracellular vesicle-based therapies are also currently being explored.
Despite increased efforts made to improve current strategies in the above mentioned diseases, there are still aspects that limit the transfer of drug delivery systems to clinical practice, including the standardization of criteria and validated methods to characterize these novel systems of drug administration, large scale-manufacturing, the use of animal models that better simulate the pathophysiological aspects of the diseases and government regulations. An additional issue that could influence their clinical translation is the overall cost-effectiveness in comparison to current therapies.
In any case it is clear that the advances achieved in nanomedicine and drug delivery technologies offer huge potential for novel therapeutic approaches to unmet medical needs such as cancer, as well as cardiovascular and neurodegenerative diseases.
Written by: Mara Blanco-Prieto [1]
[1] Department of Pharmacy and Pharmaceutical Technology, Universidad de Navarra
Reference: Elisa Garbayo, et al. Nanomedicine and drug delivery systems in cancer and regenerative medicine. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1637
Read the original:
Nanomedicine and drug delivery systems: The cutting edge of modern healthcare - Advanced Science News